Isracann Biosciences Inc.
ISCNF
$0.00
$0.000.00%
OTC PK
| 08/31/2022 | 05/31/2022 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -45.99% | -4.66% | |||
| Depreciation & Amortization | -1.22% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -45.09% | -4.57% | |||
| Operating Income | 45.09% | 4.57% | |||
| Income Before Tax | 88.59% | -340.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 88.59% | -340.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 88.59% | -340.32% | |||
| EBIT | 45.09% | 4.57% | |||
| EBITDA | 45.99% | 4.66% | |||
| EPS Basic | 89.36% | -327.27% | |||
| Normalized Basic EPS | 43.75% | 23.81% | |||
| EPS Diluted | 89.36% | -327.27% | |||
| Normalized Diluted EPS | 43.75% | 23.81% | |||
| Average Basic Shares Outstanding | 3.72% | 4.58% | |||
| Average Diluted Shares Outstanding | 3.72% | 4.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||